Continuous Glucose Monitoring and Clinical Outcomes in Diabetes on Peritoneal Dialysis

NCT07790276 | Not Yet Recruiting

• 1 other identifier: GLANCE-PD
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective, multicenter observational study will evaluate glucose profiles using continuous glucose monitoring (CGM) in 100 adults with diabetes receiving peritoneal dialysis (PD) or planning to start PD within 3 months. The study will examine associations between CGM metrics and PD regimen, glucose-lowering treatment, conventional glycemic markers, dialysis-related measures, and clinical outcomes including glycemic emergencies, hospitalizations, cardiovascular events, and mortality over 12 months.

Conditions

Continuous Glucose Monitoring; ESRD (End-Stage Renal Disease); Peritoneal Dialysis (PD); Diabetes Mellitus (DM)

Outcome Measures

Primary Outcomes (1)

• Continuous glucose monitoring-derived metrics

  CGM derived time in ranges

  During period of 14 day CGM wear

Secondary Outcomes (9)

• HbA1c

  Baseline to end of study period month 12

• 24-hour dialysate and ultrafiltration volume

  Baseline through to month 12

• Residual renal function

  From baseline through 12 months

• Hospitalization for hyperglycemic or hypoglycemic emergencies

  From baseline through 12 months

• Hospitalizations, cardiovascular events, and all-cause mortality

  From baseline through 12 months

Study Arms (2)

peritoneal dialysis group

Adults with diabetes and stage 5 chronic kidney disease who have been receiving peritoneal dialysis for at least 3 months at enrollment.

Device: Continuous glucose monitoring system

pre-peritoneal dialysis group

Adults with diabetes and stage 5 chronic kidney disease who are planned to initiate peritoneal dialysis within 3 months after enrollment.

Device: Continuous glucose monitoring system

Interventions

Continuous glucose monitoring system DEVICE

Sibionics GS3 CGM

peritoneal dialysis group; pre-peritoneal dialysis group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with diabetes and stage 5 chronic kidney disease who are receiving peritoneal dialysis or are planned to initiate peritoneal dialysis within 3 months.

You may qualify if:

• Stage 5 CKD patients
• who have received PD for at least 3 months, OR
• who are planned for PD within the next 3 months.
• Age 18-80 years old
• Known history of type 1 or type 2 diabetes for at least 3 months
• Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.
• Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.
• Willingness to abstain from swimming during their participation in the measurement phase.
• In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.
• Written informed consent to participate in the study provided by the patient.

You may not qualify if:

• Patients who are planning to switch to hemodialysis or renal transplant in the coming 3 months
• Life expectancy \<6 months
• Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites
• HbA1c \> 11% at enrolment
• Currently pregnant, as demonstrated by a positive pregnancy test at screening for women of reproductive potential.
• Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.
• Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.
• Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.
• Have a known allergy to medical-grade adhesives or known hypersensitivity to any of the products used in the study.
• Have MRI scan, CT scan, or diathermy scheduled during the proposed period of sensor wearing during the study

Sponsors & Collaborators

• Elaine Chow: lead

Study Sites (1)

Department of Medicine and Therapeutics, The Chinese University of Hong Kong

Hong Kong, Hong Kong

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Diabetes Mellitus

Interventions

Continuous Glucose Monitoring

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Blood Chemical Analysis; Clinical Chemistry Tests; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Diagnostic Techniques, Endocrine; Monitoring, Physiologic; Investigative Techniques

Study Officials

• Elaine Chow

  Department of Medicine and Therapeutics, The Chinese University of Hong Kong

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Elaine Chow

CONTACT

+85235051549; e.chow@cuhk.edu.hk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Clinical Associate Professor

Study Record Dates

• First Submitted: August 21, 2026
• First Posted: August 27, 2026
• Study Start (Estimated): August 31, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): September 1, 2028
• Last Updated: August 27, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)